Dr Sara Harter, OD | |
Unit 8900 Box 237, Dpo, AE 09831-0237 | |
(703) 349-0544 | |
Not Available |
Full Name | Dr Sara Harter |
---|---|
Gender | Female |
Speciality | Optometrist |
Location | Unit 8900 Box 237, Dpo, Armed Forces Europe |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1710956115 | NPI | - | NPPES |
2133392 | Other | VA | MAMSI |
249660 | Other | VA | PHCS |
9378577 | Other | VA | UNITED HEATHCARE |
177574 | Other | VA | ANTHEM BCBS |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
152W00000X | Optometrist | 0618001368 (Virginia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Sara Harter, OD Unit 8900 Box 237, Dpo, AE 09831-0237 Ph: (703) 349-0544 | Dr Sara Harter, OD Unit 8900 Box 237, Dpo, AE 09831-0237 Ph: (703) 349-0544 |
News Archive
Isabelle Fournier and her team are out to change surgical oncology. "Better surgery is associated with better prognosis and higher survival," said Fournier, a professor at the University of Lille and co-director of a proteomics center of INSERM, the French national institute of health.
Intestinal stem cells rejuvenate daily so bowels will stay healthy and function normally, but a new study in Cell Reports suggests they also age along with people and lose their regenerative capacity.
Bristol-Myers Squibb Company today announced results from a Phase II clinical trial in which treatment with the investigational direct-acting antiviral BMS-790052, an NS5A replication complex inhibitor, in combination with PEG-Interferon alfa and ribavirin, achieved sustained virologic response 12 weeks post-treatment in up to 92% of treatment-naïve patients chronically infected with hepatitis C genotype 1.
A recent study published on the preprint server arXiv in October 2020 shows the potential for using functionalized magnetic nanoparticles to detect the presence of the virus in a sample.
A condition of publishing in the Open Access life sciences journal F1000Research is that authors make the data underlying their findings publicly available alongside the article. Openly sharing data is an important step in helping tackle issues around the lack of reproducibility of much published research, as well as enabling data reuse.
› Verified 3 days ago